The value of the chronic rodent carcinogenicity assay in adequately predicting cancer risk in humans has become a matter of debate over the past few years. Therefore, more rapid and accurate alternative tests are urgently needed. Transgenic mouse models, those harboring genetic changes that are relevant to the multistage cancer process, may provide such alternative tests. Transgenic E&mu;-pim -1 mice, developed by Berns and coworkers in 1989, contain the pim -1 oncogene, which is expressed at elevated levels in their lymphoid compartments. As a result, these mice are predisposed to the development of T-cell lymphomas. Because of the low incidence of spontaneous tumors and the increased sensitivity to N -ethyl-N -nitrosourea-induced carcinogenesis, E&mu;-pim -1 mice were suggested to be one of the first potential and attractive candidates to be used in short-term carcinogenicity testing. In the present article, the results from 2 recent short-term assays (with mitomycin C and x-rays) are briefly presented, together with a review of all 11 performed bioassays and their corresponding histopathologic and molecular data. The overall results allow the first evaluation of the E&mu;-pim -1 mouse model with regard to its usefulness in short-term carcinogenicity testing. It has been shown that the model is primarily suitable as a sensitive short-term assay for genotoxic carcinogens that not only induce (at least) gene mutations and/or large deletions and rearrangements but that also sufficiently target the lymphoid system. However, the E&mu;-pim -1 mice lack sufficient sensitivity to justify their routine use in short-term carcinogenicity testing in general.
INTRODUCTION
Since the mid 1960s, the chronic rodent carcinogenicity assay in the rat and mouse has been considered the &dquo;gold standard&dquo; for the establishment of the carcinogenic properties of chemicals. However, several disadvantages have been linked to this chronic bioassay. For instance, large numbers of animals are needed, and the assay is very costly, laborious, and time consuming, and, therefore, less suitable for the routine screening of numerous chemicals.
Besides these practical and economic restrictions, the reliability of the chronic bioassay for the prediction of human cancer risks has since 1990 also been subject to severe criticism among scientists and regulators (1, 24) . In addition to the questionable significance of positive results observed only at the so-called maximum tolerated dose (6) , the use of specific inbred strains of rats and mice is also a major point of concern. The use of inbred strains clearly reduces variability, allowing the performance of long-term bioassays in a highly systemic fash-ion. However, these strains are also subject to &dquo;allelic enrichment&dquo; (homozygosity of most alleles), which inevitably will influence both the spontaneous and carcinogen-induced tumor incidences (21) . As a consequence, high incidences of strain-specific background tumors are often observed as are specific (single species/single tissue) carcinogen-induced tumors that may be irrelevant to humans.
The development of methods to modify specific genes in the mouse genome has provided promising new tools for generating transgenic mice that harbor specific genetic changes considered to be rate-limiting events in the multistage cancer process. Such transgenic mice, containing (for instance) an activated oncogene or an inactivated tumor suppressor gene, may provide advantages to help shorten the time required for bioassays and to improve the accuracy of carcinogen identification. Ultimately, they could replace the present chronic rodent bioassay. During the past decade, many transgenic mouse models with an activated oncogene have become available (5) . Linkage of the oncogenes to appropriate promoter and/or enhancer elements could induce high levels of transgene expression in specific tissues; as a consequence, increased rates of tumorigenesis were often observed at these sites. To be suitable for routine carcinogenicity screening, however, these models should display a low incidence of spontaneous tumors and an increased sensitivity toward (2, 23) .
EtL-pim-1 Mice
In this transgenic model, the mouse pim-1 proto-oncogene, supplemented with an upstream Ig-H-locus enhancer (E~,) and a downstream murine leukemia virus long terminal repeat (MLV LTR), is integrated into the genome of the C57BL/6 mouse strain. Ej..L-pim-1 mice, therefore, express the pim-1 transgene at elevated levels in their lymphoid compartments, and as a result are found to be predisposed to the development of T-cell lymphomas (2, 23) . The mechanism by which overexpression of the pim-1 gene in lymphoid cells mediates the enhanced susceptibility to lymphomagenesis is still unclear. However, there have been some indications that the pim-1 gene, encoding 2 related cytoplasmic serine/threonine kinases, plays a role in the growth factor response of specific hematopoietic cell types and in the inhibition of apoptosis (4, 15) . The spontaneous tumor incidence in this model is low.
Only 10-20% of E~,-pim-1 mice develop clonal T-cell lymphomas within 8 mo. After a single treatment (ip) with the carcinogen N-ethyl-N-nitrosourea (ENU), EVLpim-1 mice developed lymphomas within 3 mo in >90% of the animals, demonstrating that they are about 25-fold more sensitive to ENU than are their wild-type counterparts (2, 3) . Based on these initial results and on the ubiquitous presence of lymphoid cells throughout the body, it was suggested by the authors that these mice might also be potentially suitable for testing the carcinogenic effects of other chemicals.
Short-Term Carcinogenicity Assays
Several short-term carcinogenicity assays with predominantly point mutation-inducing genotoxic carcinogens have been performed in Ej..L-pim-1 mice since their first description in 1989 (3, (12) (13) (14) 19) . The purpose of the present article is to address the general suitability of this mouse model for short-term carcinogenicity testing. To this end, 2 short-term assays (with mitomycin C and x-rays) will be briefly presented together with a review of all presently performed bioassays and their corresponding histopathologic and molecular data. This will allow the first evaluation of the properties and overall performance of the Ej..L-pim-1 mouse as an alternative short-term cancer bioassay.
MATERIALS AND METHODS
Mitomycin C Assay. Three groups of wild-type C57BL/6 mice (for numbers of animals see Table I ) and
3 groups of heterozygous E[L-pim-1 mice were treated twice weekly (Tuesday and Thursday) by ip injection with either phosphate-buffered saline (PBS) alone or mitomycin C (Sigma) dissolved in PBS (pH 7.8; 0.2 ml/ animal). Mice at 6-8 wk of age were first adapted to the treatment by injection once per week of 0.033 mg/kg body weight (BW) (low-dose groups) and 0.13 mg/kg BW (high-dose groups) for 2 wk. Thereafter, the following dosing schedule was used. One group each of wildtype and transgenic mice served as control animals (designated group I) and were injected (twice weekly) with only the vehicle, PBS. Animals in the low-dose groups (designated group II) received 0.022 mg/kg BW per injection (twice weekly) until week 16. Because of the intermediate findings (see the Results section), the dosing for the males only was increased to 0.044 mg/kg BW per injection for 3 wk (until day 133) and again increased to 0.087 mg/kg BW until day 161 (week 23). After week 23, the dosing of the males was reduced to the starting dose of 0.022 mg/kg BW for the remainder of the exposure period, until day 399 (week 57). For high-dose groups (designated group III), treatment was continued in week 3 with twice weekly injections of 0.087 mg/kg BW, and again the doses were changed for the males to 0.175, 0.350, and 0 mg/kg BW on days 113, 134, and 162, respectively. For females in groups II and III, the dosing was increased to 0.044 and 0.175 mg/kg BW, respectively, on day 134 (week 20) and reduced to 0.022 and 0 mg/kg BW, respectively, on day 162 (week 24).
The necropsy for the control and treatment groups was carried out in week 60 of the study. Housing of the animals and all other experimental conditions were as described previously (12) .
X-Ray Assay. X-ray assays have recently been reported and were essentially carried out as outlined below (22) . At 4-7 wk of age, heterozygous E~,-pim-1 mice and their nontransgenic (wild-type) littermates were exposed to total body X-irradiation (Smart 225, Andrex; dose rate: 0.1 Gy/min) in a split-dose regimen with a 7-day interval.
The doses used were as follows: 4X 1.5 Gy (12 female [F] and 14 male [M] E~, pim-1 mice; 15 F and 18 M wild-type mice), 4X 1.0 Gy (15 F/11 M transgenic and 15 F/16 M wild-type mice), 4X 0.5 Gy (32 F/31 M transgenic and 25 F/38 M wild-type mice), or no treatment (13 F/12 M transgenic and 13 F/11 M wild-type mice). All mice were housed conventionally, with tap water and standard lab chow ad libitum. They were examined twice weekly for signs of illness and sacrificed when moribund or 250 days after the last exposure to x-rays. During the observation period of 250 days, 2 wild-type mice (exposed to 4X 1.5 Gy), 4 Eli-pim-1 mice (exposed to 4X 1.0 Gy), and 2 Ej..L-pim-1 mice and 1 wild-type mouse (all exposed to 4X 0.5 Gy) died from unknown causes and were excluded from the experiment.
The experiment with mitomycin C was performed to study the effects in E~, pim-1 mice of a genotoxic compound with DNA cross-linking properties. Mitomycin C seems to require reduction (most probably by DT-diaphorase) to become biologically active (11, 18) , and is recognized as a potent in vivo genotoxic agent toward hematopoietic cells (10, 17, 20) . Mitomycin C has been tested for carcinogenic properties in rats and mice after administration by injection techniques only, i.e., sc injection in C57BL/6 mice and ip injection in Charles River CD rats. The results indicate that mitomycin C induces almost exclusively local sarcomas by these routes of administration. Lymphoma induction was not observed (8) .
Because lymphomas were observed during the first 3 mo of the present study in only female E[L-pim-1 mice and because of the absence of any effect on BW or behavior in the male mice, the dose levels for the transgenic and wild-type males in the low-and high-dose groups were increased twice during the experiment (see the Ma- terials and Methods section). Because additional tumor responses in the female EK-pim-1 mice remained absent also, the dose levels for females were also increased later on (week 20) for both the low-and high-dose groups. Finally, the reduction on day 162 in the dosing of all males and females in the low-and high-dose groups was carried out to avoid possible cytostatic effects of mitomycin C that may preclude lymphoma development.
Minor treatment-related effects on BW (sI0% decrease, not statistically significant) were observed from day 150 onward in wild-type female mice of the highdose group and wild-type male mice of both dose groups (data not shown). In the transgenic EjjL-p~M-1 mice, no treatment-related effect on BW was observed for the females, whereas the male mice of the high-dose group had an increased BW from day 190 onward, probably because of a severe hydrothorax (see below). The cumulative doses administered to the mice and the overall results are summarized in Table I . Animals died from either lym-phoma development or severe hydrothorax. The latter can be seen as a clinical manifestation of cardiopathy. Apart from this, no further treatment-related effects were noticed on necropsy. It is clear that mitomycin C is not a potent lymphomagen for Ep,-pim-1 mice. Only a small percentage (11-30%) of the female mice developed lymphomas without a clear dose-response relationship. The tumor incidences observed were not statistically significant when subjected to the pair-wise Fisher exact test. Moreover, all 4 lymphomas were observed early in the experiment (56-92 days), whereas animals that became moribund due to a hydrothorax were observed from day 200 onward in the high-dose groups of the transgenic males and both sexes of wild-type mice.
X-Ray Assay
The experiment with total body X-irradiation was performed (22) to study the effects in Ep,-pim-1 mice of a genotoxic agent that is known to predominantly cause DNA strand breaks. This will result mainly in chromosomal deletions, rearrangements, and amplifications (7) . The agent, moreover, is also a potent lymphomagen in wild-type mice (9) . Within the scope of this review, the study also serves as a good illustration of what is to be expected in terms of a positive tumor response.
Groups of transgenic and wild-type mice were exposed to 4 weekly doses of x-rays as described in the Materials and Methods section. Monitoring for lymphoma development was continued for 250 days after the last exposure, and untreated Ep, pim-1 and wild-type mice served as control groups. All Ej..L-pim-l mice exposed to the highest x-ray dose developed lymphomas within 250 days (see Fig. 1 ), whereas 12 of the 31 equally treated wild-type animals survived this period without showing any behavioral or macroscopic pathological signs of lymphoma development (at autopsy). Of the recipients of the 2 lower doses of x-rays (4X 1.0 Gy, 4X 0.5 Gy), 20 of 22 and 17 of 61 Ep, pim-1 mice, respectively, developed a lymphoma. In contrast, only 6 of 31 mid-dose and 0 of 62 low-dose wild-type mice exposed to the same doses of x-rays developed lymphomas ( Fig. 1 ). From these data it can be calculated, as described by Breuer et al (3) , that the E[L-pim-1 mice were at least 3-fold more sensitive to fractionated total body X-irradiation than the wild-type mice (littermates). Remarkably, at all x-ray doses tested, female transgenic and nontransgenic mice developed lymphomas somewhat earlier than the corresponding male mice. However, at the end of the observation period, similar lymphoma incidences were found in male and female mice in each treatment group (data not shown).
Histopathologic analysis of the macroscopically identified lymphomas showed the characteristics of lymphoblastic lymphoma, as observed in the spontaneous tumors in E)JL-/?wz-l mice as well. Most lymphomas (92%) were classified as T-cell lymphomas (22) . Molecular analysis of lymphomatous tissue (spleen/thymus) demonstrated that in 75% of all lymphomas, c-myc mRNA levels were 5to 20-fold higher than those in control spleen/thymus tissues. Also, the levels of endogenous pim-1 transcripts were elevated significantly in 16% of the x-ray-induced lymphomas in Ep, pim-1 mice. The expression of other FIG. 1.-Lymphoma incidence in ER-pim-1 mice and wild-type littermates exposed to fractionated total body X-irradiation (4X 1.5 Gy, 4X 1.0 Gy, 4X 0.5 Gy, or left untreated). Solid lines indicate the lymphoma-free survival of Eli-pim-1 mice, dashed lines indicate the lymphoma-free survival of wild-type mice, as judged by macroscopic analysis at autopsy and subsequent histologic examination. The lines represent the combined results of male and female mice. oncogenes, previously found to be activated in combination with pim-1 in lymphomagenesis (pal-I, frat-1, and tiam-1), and also of the mdm-2 and mdm-x oncogenes appeared not to be affected. Finally, deletions or rearrangements of the p16 and p15 tumor suppressor genes were seldom observed (22) . DISCUSSION 
Assays with Mitomycin C and X-Rays
The results obtained with mitomycin C seem somewhat puzzling. After the few early lymphomas observed in female E[L-pim-1 mice, the absence of any further lymphoma development throughout the entire exposure period of 399 days is surprising. This despite the fact that we made an intermediate increase in the dosing regimen and extended the observation period. However, the testing of even higher dose levels would not appear to be possible because of the observed development of hydrothorax. Also, the absence of any spontaneous lymphomas in the control E~, pim-1 mice is somewhat remarkable, particularly in the case of the females. However, low numbers of mice were used in the control groups (10) (11) (12) , and the rates of spontaneous lymphoma development in Ej..L-pim-1 mice may vary from experiment to experiment (males 0-10% after 40 wk, females 11-40% after 40 wk; refs. 3, [12] [13] [14] 19) .
It is difficult to compare the accumulated dose levels applied in this experiment (i.e., 2.67 to 6.55 mg/kg BW) (Table I) , with the previously reported sc injection in wild-type C57BL/6 mice. However, a somewhat similar dosing schedule (ip thrice weekly for 6 mo), leading to comparable cumulative doses (2.9 to 11.7 mg/kg BW), gave rise to local sarcomas in CD rats after an observation period of 18 mo. In Ej..L-pim-1 mice, a very limited and inverse dose-related lymphoma induction was ob-served in the females only. An explanation could be that mitomycin C may act as a weak lymphomagen for female transgenic mice and that it simultaneously acts as a potent cytostatic agent, especially at higher dose levels. However, the observation that decreasing the dose levels again after day 161 (week 23) did not result in lymphoma development later on seems to argue against such an explanation.
The results of the assay with total body X-irradiation demonstrate that EjjL-p~M-1 mice are highly susceptible to lymphomagenesis induced by a directly acting carcinogenic agent that induces large chromosomal deletions and rearrangements rather than point mutations. For all doses of x-ray tested, exposed E)JL-pw!-l mice developed lymphomas at higher incidences and with shorter latency times than did wild-type mice or untreated ER-pim-1 mice (Fig. 1) . Also, a clear dose-response relationship is observed. Furthermore, the results obtained for the x-raytreated wild-type mice correspond well with data found in the literature on lymphomagenesis in C57BL/6J mice (9) .
Summary of All Reported Short-Term Carcinogenicity Assays
Including the experiments noted above, a total of 11 1 known carcinogens have now been tested in short-term carcinogenicity assays with E[L-pim-1 mice (3, 12-14, 19, 22) . The compounds differed in their genotoxic properties, their requirements for metabolic activation, their application routes, and their tumor target tissues in wildtype mice. Included were typical model carcinogens like ENU, 2-acetyl-aminofluorene (2-AAF), N,N-diethylnitrosamine (DEN), and mitomycin C; environmental agents like benzo[a]pyrene (B[a]P), benzene, 1,2-dichloroethane (DCE), and x-rays; and food-related carcinogens like 2- a Measured in mg/kg BW, unless otherwise stated. 6 Tumors in wild-type mice. I Spontaneous lymphoma incidence varies from 0-10% (males) and from 0-40% (females) after 40 wk. d Also clastogenic in mouse bone marrow.
amino-1 -methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), and 2-amino-3-methylimidazo[4,5-f] quinoline (IQ). A summary of the results obtained is presented in Table II . The observation period of most studies lies between 30 and 40 wk but has been extended to 44 and 60 wk, respectively, for the negative studies with 12-0-tetra decanoylphorbol-13-acetate (TPA) and mitomycin C. The dosing periods varied from single exposures (ENU), 4 weekly exposures (x-rays), 2-3 exposures per week for shorter (B[a]P) or longer (TPA, mitomycin C) time periods, to daily exposures throughout the whole observation period (2-AAF, DEN, DCE, benzene, PhIP, and IQ). Clear positive results (i.e., a higher tumor incidence and shorter latency time compared with nontransgenic control mice exposed to the same dose) are observed only for those carcinogens that are genotoxic, inducing at least point mutations or large deletions and rearrangements, and are also known to induce lymphomas in wild-type rodents. The capability of inducing clastogenic effects in the bone marrow of the mouse seems to bear little significance to the lymphomagenic potential in Ej..L-pim-1 mice (see Table II ). Clear dose-response relationships in lymphoma incidence were observed for some of the test agents that were positive (indicated as &dquo;dr&dquo; in Table II ).
Marked differences in the response between the sexes were observed for some compounds, e.g., B[a]P (males > females) and PhIP (females > males), and to a lesser extent for x-rays and mitomycin C (females > males for both). The extent of the increase in sensitivity of E[L-pim-1 mice compared with nontransgenic mice seems to vary with the agent tested (e.g., 25 -fold for ENU, 5-fold for B [a]P, and 3-fold for x-rays). It is possible that the age at which the animals were treated may have affected this sensitivity, because ENU was administered at 2 wk of age, whereas B[a]P and the x-rays were started at 4-8 wk of age.
The data presently available indicate that organ specificity rather than type of genotoxic lesion or mutation spectra induced by the (pro)carcinogen determines the susceptibility of the Ej..L-pim-1 mice. It also cannot be excluded that the observed differences in sensitivity noted above in part reflect differences in target tissue specificity. For instance, for B[a]P the lymphoid system appears to be a minor target site in wild-type mice compared with forestomach tumors (12) . Thus, genotoxic carcinogens that have the lymphoid tissue only as a minor target site might still be identified within the short-term testing period. However, it is questionable whether the E[L-pim-1 mice will always confer sufficient sensitivity for this to occur. On the other hand, genotoxic carcinogens known not to target the lymphoid tissue (in wildtype mice) will probably not be readily identified in this transgenic mouse model, as is illustrated by the marginal positive responses obtained with the potent carcinogens 2-AAF, DEN, and DCE, and the negative result with IQ.
The DNA-reactive agent mitomycin C (cross-linking agent) gave only a marginal (i.e., not statistically significant) positive response. Also, the known clastogenic human carcinogen (and mouse lymphomagen) benzene and the nongenotoxic tumor promoter TPA appeared to be negative within the short-term testing period. Although as yet difficult to explain, these results clearly detract from the general applicability of this mouse model for the routine carcinogenicity screening of chemicals.
Features of Lymphomas in Etk-pim-1 Mice
The types of tumors that develop, both spontaneously and by carcinogen induction, are primarily multicentric or generalized T-cell lymphomas, but occasionally also a B-cell lymphoma is observed (22) . Because of their rapid progression and life-threatening nature, the occurrence of these lymphomas is easy to monitor by noting several clinical signs and animal behaviors. This easy way of inlife detection also represented one of the attractive features of using the E[L-pim-1 mouse model in short-term carcinogenicity tests. At autopsy, enlargements of the thymus, spleen, and peripheral and mesenteric lymph nodes are often observed (Fig. 2 ). Histopathologic anal- (14) . ysis of the macroscopically identified lymphomas reveals features consistent with a lymphoblastic lymphoma/leukemia as classified by World Health Organization/International Agency for Research on Cancer (16, 25) with infiltration of lymphatic organs (Fig. 3 ). In addition, lymphoma cell infiltrates were also observed frequently in nonlymphatic organs such as liver, kidney, lung, and, more infrequently, in ovaries, testis, heart, intestine, and skeletal muscle. Molecular analysis of the T-cell lymphomas in EVLpim-1 mice has originally demonstrated an increased level of c-myc expression in the great majority of spontaneous and ENU-induced tumors (2, 3, 23) . The same was observed to a lesser extent for the endogenous pim-1 I gene. On the other hand, activating ras gene mutations were only infrequently detected. In some of the later studies, as summarized in this article, these results have in part been confirmed and/or extended. Increased levels of c-myc mRNA were also observed in the majority of lymphomas (75-80%) induced by B[a]P and x-rays, whereas no increased expression of N-myc was observed (12, 22) . No activating ras mutations or enhanced p53 immunostaining were found in the B[a]P-induced lymphomas (12) . A very low frequency of lymphomas in DEN-and 2-AAF-treated Ej..L-pim-1 mice (1/11 [9%] and 1/18 [6%], respectively) had mutations in the p53 gene, whereas no mutations were found in exons 5-8 in 8 lymphomas from control animals or in 7 and 11 lymphomas from benzene and DCE-treated mice, respectively (Storer et al, unpublished observations). In the x-ray-induced lymphomas, the expression of other oncogenes, previously found to be activated in combination with pim-1 in lymphomagenesis (pal-I, frat-I, and tiam-1), was not altered. Also, the expression levels of mdm-2 and mdm-x were not affected, and deletions and rearrangements of the P16 and p15 tumor suppressor genes were seldom observed (22) .
Finally, similar to the observations for ENU, the levels (14) . of endogenous pim-1 transcripts were elevated significantly in 16% of the x-ray-induced lymphomas (22) .
Evaluation of El-t-pim-1 Mouse Model
Transgenic E~,-pim-1 mice express an (activated) pim-1 oncogene at elevated levels in their lymphoid compartments and, as a consequence, have been found to be predisposed to the development of T-cell lymphomas (2, 23) . The spontaneous tumor incidence in this model is low, whereas treatment with certain carcinogens, such as ENU, leads to a rapid induction of mainly generalized Tcell lymphomas. The lymphomas represent an elegant detection system because they are easy to monitor by noting several clinical signs and animal behaviors. This renders the E~,-pim-1 mouse model a potential and attractive candidate for use in short-term carcinogenicity test.
Although only a limited number of chemical classes and individual compounds (agents) have been tested thus far (this article and references 3, 12-14, 19, 22) , the results allow for an initial evaluation of the Ej..L-pim-1 model. The model appears suitable primarily as a sensitive short-term assay for genotoxic carcinogens that not only induce (at the least) gene mutations and large deletions and rearrangements but that also sufficiently target the lymphoid system. Carcinogens not fulfilling these criteria are unlikely to be detected within the duration period of the short-term assay (6-9 mo). Despite these limitations, the model is being used at present to investigate certain kinds of genotoxic chemicals for their lymphomagenic properties. However, for the identification of a broad range of carcinogens with different target tissues, the ERpim-1 mice lack sufficient sensitivity to justify their routine use in short-term carcinogenicity testing.
